1435.1 – Processing and Cryopreservation of Ovarian Tissue

Re-submission.

The proposed medical service is for processing and cryopreservation (freezing) of ovarian tissue (partial or whole ovary removal), for fertility preservation both prior to receiving or following completion of gonadotoxic treatment for malignant or non-malignant conditions in patients aged 0-40 years, and for thawing and preparation of ovarian tissue prior to ovarian tissue transplant (OTT) in patients wanting to have a biological pregnancy if they are infertile.

Type: Therapeutic

The proposed patient population is defined by the requirement of gonadotoxic therapy. Specifically, the proposed population is females aged 0 to 40 years (pre pubertal and post pubertal) who are scheduled to undergo, or have completed gonadotoxic treatment. Gonadotoxic treatment includes any treatment which is associated with an intermediate or high risk of ovarian damage or sterility. This can include treatment such as chemotherapy, conditioning therapy for bone-marrow transplantation, pelvic surgery, or pelvic irradiation. Cancer is the primary group of diseases for which women are likely to undergo gonadotoxic treatment and would account for an estimated 78% of cases eligible for OTC.

• PASC meeting: 11 - 12 August 2016
• ESC meeting: 13 June 2019
• MSAC meeting: 1-2 August 2019